Puma Biotechnology (PBYI) Resumen de Acciones
Puma Biotechnology, Inc. es una empresa biofarmacéutica centrada en el desarrollo y la comercialización de productos para mejorar la atención oncológica en Estados Unidos y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 0/6 |
| Rendimiento pasado | 2/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
PBYI Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Puma Biotechnology, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$9.05 |
| Máximo en las últimas 52 semanas | US$9.74 |
| Mínimo de 52 semanas | US$4.30 |
| Beta | 1.23 |
| Cambio en 1 mes | 4.14% |
| Variación en 3 meses | 25.17% |
| Cambio de 1 año | 99.34% |
| Variación en 3 años | 169.35% |
| Variación en 5 años | 30.03% |
| Variación desde la OPV | -32.96% |
Noticias y actualizaciones recientes
Seeking Alpha • Sep 08
Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise
Summary NERLYNX gives PBYI an established revenue stream that can support alisertib’s development into a potential second oncology franchise. Currently, PBYI already has positive cash flows and a healthy balance sheet, which I believe should give them flexibility as their R&D progresses. Alisertib’s biomarker strategy could identify responsive patients, but bear in mind that it’s still a speculative asset in Phase 2 trials. The main risk is that PBYI needs a new franchise before NERLYNX’s generic competition in 2030 starts making a dent in their revenue base. However, for now, I believe PBYI’s valuation and prospects warrant a speculative “Buy” for long-term investors seeking exposure to oncology assets. Read the full article on Seeking Alpha
Actualización de narrativa • Aug 08
PBYI: Raised 2026 Guidance Will Still Likely Fail To Justify Pricing
Analysts have raised their price target on Puma Biotechnology to $6.00 from $5.00, citing updated assumptions that include a revised fair value estimate, a slightly higher discount rate, a less pronounced decline in revenue growth expectations, a stronger profit margin outlook, and a modestly lower future P/E multiple. What’s in the News for Puma Biotechnology Puma Biotechnology issued earnings guidance for the third quarter of 2026, with expected total revenue of US$56 million to US$59 million and projected net income of US$2 million to US$3.5 million.Recent updates
Seeking Alpha • Sep 08
Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise
Summary NERLYNX gives PBYI an established revenue stream that can support alisertib’s development into a potential second oncology franchise. Currently, PBYI already has positive cash flows and a healthy balance sheet, which I believe should give them flexibility as their R&D progresses. Alisertib’s biomarker strategy could identify responsive patients, but bear in mind that it’s still a speculative asset in Phase 2 trials. The main risk is that PBYI needs a new franchise before NERLYNX’s generic competition in 2030 starts making a dent in their revenue base. However, for now, I believe PBYI’s valuation and prospects warrant a speculative “Buy” for long-term investors seeking exposure to oncology assets. Read the full article on Seeking AlphaActualización de narrativa • Aug 08
PBYI: Raised 2026 Guidance Will Still Likely Fail To Justify Pricing
Analysts have raised their price target on Puma Biotechnology to $6.00 from $5.00, citing updated assumptions that include a revised fair value estimate, a slightly higher discount rate, a less pronounced decline in revenue growth expectations, a stronger profit margin outlook, and a modestly lower future P/E multiple. What’s in the News for Puma Biotechnology Puma Biotechnology issued earnings guidance for the third quarter of 2026, with expected total revenue of US$56 million to US$59 million and projected net income of US$2 million to US$3.5 million.Actualización de narrativa • Jun 06
PBYI: 2026 Revenue Guidance Will Likely Still Fail To Justify Pricing
Analysts have kept their $5.00 price target on Puma Biotechnology broadly aligned with prior estimates, reflecting only small adjustments to the discount rate, revenue growth assumptions, profit margin outlook and future P/E inputs in their valuation work. What's in the News Puma Biotechnology raised full year 2026 guidance, now expecting total revenue of US$222 million to US$229 million and net income of US$16 million to US$19 million, citing increased demand for NERLYNX.Actualización de narrativa • May 19
PBYI: 2026 Profit Outlook Will Likely Fail To Justify Current Pricing
Analysts have adjusted their price target on Puma Biotechnology to reflect updated views on fair value at $5.00. This change is accompanied by revised assumptions regarding the discount rate, revenue growth, profit margins, and a higher future P/E multiple.Artículo de análisis • May 15
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
Puma Biotechnology, Inc.'s ( NASDAQ:PBYI ) earnings announcement last week didn't impress shareholders. However, our...Artículo de análisis • May 11
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
A week ago, Puma Biotechnology, Inc. ( NASDAQ:PBYI ) came out with a strong set of first-quarter numbers that could...Actualización de narrativa • Apr 28
PBYI: 2026 Profit Outlook Will Likely Fail To Justify Current Pricing
Analysts have adjusted their price target on Puma Biotechnology slightly, with the updated fair value moving to $5.00. This reflects refreshed views on the discount rate, long-term revenue growth, profit margins, and future P/E assumptions.Actualización de narrativa • Apr 11
PBYI: 2026 Profitability Guidance Will Likely Fail To Support Current Pricing
Analysts have slightly adjusted their price target on Puma Biotechnology, keeping fair value around $5.00 while fine tuning inputs such as discount rate, revenue growth, profit margin, and future P/E to reflect updated assumptions about the company’s risk profile and earnings potential. What's in the News Puma Biotechnology issued new earnings guidance for the first quarter of 2026, projecting net product revenue of US$36 million to US$39 million and royalty revenue of US$2 million to US$3 million, for total revenue of US$38 million to US$42 million, with an expected net loss of US$8 million to US$10 million (company guidance).Actualización de narrativa • Mar 28
PBYI: 2026 Guidance Will Likely Fail To Justify Current Pricing
Analysts have modestly adjusted their price target on Puma Biotechnology, reflecting small refinements to assumptions around the discount rate, revenue growth, profit margins, and forward P/E rather than a major shift in the outlook. What's in the News Puma Biotechnology issued earnings guidance for the first quarter of 2026, projecting net product revenue of US$36 million to US$39 million and royalty revenue of US$2 million to US$3 million, for total revenue of US$38 million to US$42 million (Key Developments).Actualización de narrativa • Mar 13
PBYI: Index Inclusion Will Likely Fail To Offset Weak Revenue Outlook
Analysts have trimmed their price target on Puma Biotechnology to $5.00 from $5.00 in response to updated assumptions regarding discount rates, revenue growth, profit margins, and future P/E. These changes leave the fair value estimate effectively unchanged.Actualización de narrativa • Feb 26
PBYI: Index Addition And Refined Assumptions Will Still Limit Upside Potential
Analysts have adjusted their price target on Puma Biotechnology to reflect an updated fair value of $5.00, a slightly lower discount rate of 7.25%, almost unchanged revenue growth at about 97%, a stable profit margin near 11.02%, and a marginally different future P/E of roughly 13.33x, indicating a largely intact valuation framework with only fine tuning to their assumptions. What's in the News Puma Biotechnology, Inc.Actualización de narrativa • Feb 11
PBYI: Index Inclusion And Higher Multiple Will Likely Fail To Support Upside
Analysts have raised their price target on Puma Biotechnology to $5.00 from $3.50, citing updates to fair value estimates, discount rate assumptions, and expected future P/E levels. What's in the News Puma Biotechnology, Inc.Actualización de narrativa • Jan 26
PBYI: Higher 2025 Guidance And Index Addition Will Not Sustain Current Optimism
Analysts have slightly adjusted their price target on Puma Biotechnology, citing modest tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E. Together, these changes translate into a small refinement in estimated fair value rather than a major reset in outlook.
Actualización de narrativa • Jan 12
PBYI: Higher 2025 Guidance And Index Inclusion Will Still Look Overpriced
Analysts have lifted their price targets on Puma Biotechnology, citing updates to their models that reflect a fair value estimate of $5.00, adjusted discount rates, revised revenue growth assumptions of about 1% instead of a 3% decline, higher projected profit margins of around 10% compared with about 3%, and a lower assumed future P/E multiple near 14 versus about 37. What's in the News Puma Biotechnology, Inc.Actualización de narrativa • Dec 26
PBYI: Raised 2025 Guidance Will Still Fail To Support Current Optimism
Analysts have modestly trimmed their price target on Puma Biotechnology to reflect a slightly lower future earnings multiple, even as estimates for fair value and long term growth remain largely unchanged. What's in the News Puma Biotechnology has been added to the NASDAQ Biotechnology Index, increasing its visibility among biotech-focused investors (index announcement).Actualización de narrativa • Dec 12
PBYI: 2025 Revenue Guidance Will Fail To Justify Current Optimism
Analysts have modestly adjusted their price target on Puma Biotechnology higher, now seeing slightly improved valuation support in light of stable fair value estimates and marginally lower perceived risk in the companys long term outlook. What's in the News Puma Biotechnology issued new fourth quarter 2025 guidance, projecting total revenue between $67 million and $70 million and net income of $9 million to $11 million (company guidance).Artículo de análisis • Dec 09
With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Actualización de narrativa • Nov 27
PBYI: Rising Discount Rate Will Undermine Earnings Momentum In 2025
Analysts have slightly lowered their price target for Puma Biotechnology, citing marginal revisions in key financial estimates. This resulted in a new target of $3.50 per share, which remains unchanged from the previous assessment.Artículo de análisis • Nov 13
Puma Biotechnology's (NASDAQ:PBYI) Shareholders May Want To Dig Deeper Than Statutory Profit
The market shrugged off Puma Biotechnology, Inc.'s ( NASDAQ:PBYI ) solid earnings report. We think that investors might...Actualización de narrativa • Nov 09
PBYI: Rising Discount Rate And Weak Revenue Outlook Will Pressure Earnings
Analysts have raised their price target for Puma Biotechnology from $3.00 to $3.50, citing improved revenue growth projections and stronger expected profit margins. What's in the News Puma Biotechnology issued new earnings guidance for the fourth quarter of 2025, projecting total revenue between $67 million and $70 million, and net income between $9 million and $11 million (Key Developments).Artículo de análisis • Oct 18
Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Catapults 26% Though Its Price And Business Still Lag The Market
Puma Biotechnology, Inc. ( NASDAQ:PBYI ) shares have continued their recent momentum with a 26% gain in the last month...Artículo de análisis • Sep 11
Does Puma Biotechnology (NASDAQ:PBYI) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Artículo de análisis • Aug 12
Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Catapults 43% Though Its Price And Business Still Lag The Market
NasdaqGS:PBYI 1 Year Share Price vs Fair Value Explore Puma Biotechnology's Fair Values from the Community and select...Artículo de análisis • Aug 09
We Ran A Stock Scan For Earnings Growth And Puma Biotechnology (NASDAQ:PBYI) Passed With Ease
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Artículo de análisis • May 20
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Fly 25% But Investors Aren't Buying For Growth
Puma Biotechnology, Inc. ( NASDAQ:PBYI ) shareholders have had their patience rewarded with a 25% share price jump in...Seeking Alpha • Apr 11
Puma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline Potential
Summary Initiate coverage of Puma Biotechnology with a Hold rating due to limited near-term upside, competitive landscape, and uncertain pipeline outlook. NERLYNX adoption is hindered by side effects and competition, while alisertib is still in early development with modest expectations. Puma's cash runway may extend several years, but that could change with faltering revenues for NERLYNX, new drug additions, or other unforeseen pipeline developments. Legal issues and competitive pressures contribute to the cautious outlook, with no clear signs of growth or turnaround. Read the full article on Seeking AlphaArtículo de análisis • Mar 10
Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 26%
Puma Biotechnology, Inc. ( NASDAQ:PBYI ) shares have had a really impressive month, gaining 26% after a shaky period...
Nueva narrativa • Feb 09
Alisertib Trials And International NERLYNX Approvals Will Expand Market, But Single Product Dependence And Safety Concerns Could Limit Gains
Strategic collaborations and regulatory approvals in international markets are expected to drive global revenue growth and increase overall sales.Artículo de análisis • Jan 14
Insufficient Growth At Puma Biotechnology, Inc. (NASDAQ:PBYI) Hampers Share Price
You may think that with a price-to-sales (or "P/S") ratio of 0.6x Puma Biotechnology, Inc. ( NASDAQ:PBYI ) is...Seeking Alpha • Dec 16
Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward
Summary Puma Biotechnology focuses on expanding neratinib sales and developing alisertib for breast and lung cancers, despite recent stock declines. Neratinib sales are stagnant, but the company remains stable financially. Alisertib shows early efficacy signals, with phase 2 trials ongoing, but its future success remains uncertain. Despite market skepticism, I maintain a "Buy" sentiment due to PBYI's favorable financial status and potential growth from alisertib. Read the full article on Seeking AlphaArtículo de análisis • Nov 14
Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest
When companies post strong earnings, the stock generally performs well, just like Puma Biotechnology, Inc.'s...Artículo de análisis • Sep 07
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Artículo de análisis • Aug 15
Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop
To the annoyance of some shareholders, Puma Biotechnology, Inc. ( NASDAQ:PBYI ) shares are down a considerable 26% in...Rentabilidad de los accionistas
| PBYI | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | -6.6% | -4.4% | -0.2% |
| 1Y | 99.3% | 39.9% | 14.8% |
Rentabilidad vs. Industria: PBYI superó a la industria US Biotechs, que obtuvo un rendimiento del 39.9% el año pasado.
Rentabilidad vs. Mercado: PBYI superó al mercado US, que obtuvo un rendimiento del 14.8% el año pasado.
Volatilidad de los precios
| PBYI volatility | |
|---|---|
| PBYI Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Precio estable de las acciones: PBYI no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de PBYI (6%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2010 | 179 | Alan Auerbach | www.pumabiotechnology.com |
Puma Biotechnology, Inc, empresa biofarmacéutica, se centra en el desarrollo y la comercialización de productos para mejorar la atención oncológica en Estados Unidos y a escala internacional. Ofrece NERLYNX, una versión oral de neratinib que se utiliza para tratar a pacientes adultos con cáncer de mama HER2-sobreexpresado/amplificado en fase inicial; y cáncer de mama HER2-positivo avanzado o metastásico cuando se combina con capecitabina. La empresa también desarrolla alisertib, una pequeña molécula inhibidora de la aurora quinasa A para el tratamiento del cáncer de mama con receptores hormonales positivos, el cáncer de mama triple negativo, el cáncer de pulmón microcítico y el cáncer de cabeza y cuello.
Resumen de fundamentos de Puma Biotechnology, Inc.
| Estadísticas fundamentales de PBYI | |
|---|---|
| Capitalización bursátil | US$484.71m |
| Beneficios(TTM) | US$26.72m |
| Ingresos (TTM) | US$231.24m |
17.5x
Ratio precio-beneficio (PE)2.0x
Ratio precio-ventas (PS)¿Está PBYI sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de PBYI | |
|---|---|
| Ingresos | US$231.24m |
| Coste de los ingresos | US$58.20m |
| Beneficio bruto | US$173.05m |
| Otros gastos | US$146.33m |
| Beneficios | US$26.72m |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 0.52 |
| Margen bruto | 74.83% |
| Margen de beneficio neto | 11.55% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado PBYI a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/09 13:02 |
| Precio de las acciones al final del día | 2026/09/09 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Puma Biotechnology, Inc. está cubierta por 13 analistas. 0 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Geoffrey Meacham | BofA Global Research |
| Yigal Nochomovitz | Citigroup Inc |
| Paul Choi | Goldman Sachs |